FDA Working Group Considering Changes To OTC Cough/Cold Monograph
This article was originally published in The Tan Sheet
Executive Summary
An FDA working group conducting a review of OTC cough and cold medicines for 2- to 11-year-old children will make recommendations this spring on actions the agency should take concerning use of the products for that age group, Office of Nonprescription Products officials said Jan. 17
You may also be interested in...
FDA Faces “Conundrum” In Determining Efficacy Of Children’s Cold Products
FDA Office of New Drugs Director John Jenkins is uncertain the efficacy of OTC cough/cold ingredients can be accurately assessed in a pediatric population
FDA Faces “Conundrum” In Determining Efficacy Of Children’s Cold Products
FDA Office of New Drugs Director John Jenkins is uncertain the efficacy of OTC cough/cold ingredients can be accurately assessed in a pediatric population
FDA Faces “Conundrum” In Determining Efficacy Of Children’s Cold Products
FDA Office of New Drugs Director John Jenkins is uncertain the efficacy of OTC cough/cold ingredients can be accurately assessed in a pediatric population